Hydromorphone for cancer pain

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 5, 2014, Pages

  Bao, Yan J ^a   Hou, Wei ^a   Kong, Xiang Y ^a   Yang, Liping ^a   Jones, Katie ^b   Xia, Jun ^c   Hua, Bao J ^a  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b Systematic Review Solutions Ltd   (China)

^c Systematic Review Solutions Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROMORPHONE;

ANALGESIA; ARTICLE; CANCER PAIN; CONSTIPATION; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; HUMAN; NAUSEA; PAIN ASSESSMENT; PAIN INTENSITY; PRIORITY JOURNAL; QUALITY OF LIFE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

EID: 84936845742     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD011108     Document Type: Article

References (25)

1. Binsfeld H, Szczepanski L, Waechter S, Richarz U, Sabatowski R. A randomized study to demonstrate noninferiority of once-daily OROS® hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain. Pain Practice 2010;10(5):404-15.
2. Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, et al.Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. The Lancet Oncology 2012;13(2):e58-68.
3. Grahame-Smith DG, Aronson JK. Oxford Textbook of Clinical Pharmacology and Drug Therapy. III Edition. Oxford: Oxford University Press, 2002.
4. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
5. Merskey H, Bogduk N. Part III: Pain terms, a current list with definitions and notes on usage. Classification of Chronic Pain. 2nd Edition. Seattle: IASP Task Force on Taxonomy, IASP Press, 2011 [update from 1994].
6. King S, Forbes K, Hanks GW, Ferro CJ, Chambers EJ. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. Palliative Medicine 2011;25(5):525-52.
7. Laird B, Colvin L, Fallon M. Management of cancer pain: basic principles and neuropathic cancer pain. European Journal of Cancer 2008;44:1078-82.
8. Miller MG, McCarthy N, O'Boyle CA, Kearney M. Continuous subcutaneous infusion of morphine vs. hydromorphone: a controlled trial. Journal of Pain and Symptom Management 1999;18(1):9-16.
9. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine 2009;6(7):1-6.
10. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD008242.pub2]
11. Moore RA, Straube S, Aldington D. Pain measures and cut-offs -'no worse than mild pain' as a simple, universal outcome. Anaesthesia 2013;68(4):400-12.
12. Murray A, Hagen NA. Hydromorphone. Journal of Pain and Symptom Management 2005;29(5):57-66.
13. Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG, et al.Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ 2010;341:c3515.
14. Pigni A, Brunelli C, Caraceni A. The role of hydromorphone in cancer pain treatment: a systematic review. Palliative Medicine 2011;25(5):471-7.
15. Portenoy RK, Lesage P. Management of cancer pain. The Lancet 1999;353:1695-700. [DOI: 10.1016/S0140-6736(99)01310-0]
16. Portenoy RK. Treatment of cancer pain. The Lancet 2011;377(9784):2236-47.
17. Running A, Turnbeaugh E. Oncology pain and complementary therapy. Clinical Journal of Oncology Nursing 2011;15(4):374-9.
18. Sarhill N, Walsh D, Nelson KA. Hydromorphone: pharmacology and clinical applications in cancer patients. Support Care Cancer 2001;9(2):84-96.
19. Twycross RG. Pain Relief in Advanced Cancer. Singapore: Churchill Livingstone, 1994:279.
20. Urquhart ML, Klapp K, White PF. Patient controlled analgesia: a comparison of intravenous versus subcutaneous hydromorphone. Anesthesiology 1988;69:428-32.
21. Van den Beuken-van Everdingen MHJ, De Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Annals of Oncology 2007;18(9):1437-49.
22. World Health Organization. Cancer Pain Relief. 2nd Edition. Geneva: WHO, 1986.
23. Wiffen PJ, Wee B, Moore RA. Oral morphine for cancer pain. Cochrane Database of Systematic Reviews 2013, Issue 7. [DOI: 10.1002/14651858.CD003868.pub3]
24. Yakovlev AE, Ellia Y. Spinal cord stimulation as a treatment option for intractable neuropathic cancer pain. Clinical Medicine & Research 2008;6(3-4):103-6.
25. Quigley C. Hydromorphone for acute and chronic pain. Cochrane Database of Systematic Reviews 2013, Issue 10. [DOI: 10.1002/14651858.CD003447.pub2]